Stay updated on Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.

Latest updates to the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page
- Check4 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2, and the Back to Top element was removed.SummaryDifference0.1%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.1%
- Check18 days agoChange DetectedThe web page has been updated to include a new facility name and location, as well as specific medical topics related to colorectal cancer and various antibodies and proteins. Additionally, the version has been updated from v2.16.12 to v3.0.0.SummaryDifference2%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.7%
Stay in the know with updates to Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Binimetinib+Bevacizumab in Refractory CRC Clinical Trial page.